What if you could fix disease by rewriting DNA? From CRISPR to next-gen gene editing, Stephanie Sirota and Beam Therapeutics CEO John Evans break down base editing, prime editing, and the path to one-time cures.

PODCAST TEAM

Producer & Director: Devon Leaver

Editor: Dominique Guerra

Production Coordinator: Ying Yu Lin

Production support: Annabelle Chan

Executive Editorial Advisor: Stephanie Sirota

Research Consultant: Piratip Pratumsuwan

Theme music by: Yehezkel Raz

Additional music: APM Music

Featuring: John Evans, CEO and Board Member of Beam Therapeutics, moderated by Stephanie Sirota, Partner and Chief Business Officer at RTW Investments.

FOLLOW US

Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.

To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify, Apple Podcasts, Amazon Music, and most other podcast platforms.

CHAPTERS

00:00 – Introduction

1:15 – Gene Editing, Gene Therapy, Base and Prime Editing

4:18 – Challenges in Gene Editing

6:09 – In Vivo and Ex Vivo

9:33 – What is A1AT Deficiency?

13:44 – Safety in Gene Editing

15:52 – AI and Beam Therapeutics

21:25 – John Evans’ Journey into Biotech

23:06 – Outro

DISCLAIMER

This interview was given by John Evans, CEO and Board Member of Beam Therapeutics, and moderated by Stephanie Sirota, Partner and Chief Business Officer at RTW Investments. Statements reflect RTW's views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent.